US Stock MarketDetailed Quotes
IKT Inhibikase Therapeutics
- 2.0400
- -0.0600-2.86%
Close Apr 19 16:00 ET
- 2.0100
- -0.0300-1.47%
Post 16:37 ET
13.40MMarket Cap-571P/E (TTM)
2.1300High2.0200Low52.73KVolume2.1200Open2.1000Pre Close108.39KTurnover0.93%Turnover RatioLossP/E (Static)6.57MShares4.351252wk High1.22P/B11.55MFloat Cap0.790052wk Low--Dividend TTM5.66MShs Float70.8000Historical High--Div YieldTTM5.24%Amplitude0.7900Historical Low2.0550Avg Price1Lot Size
Inhibikase Therapeutics Stock Forum
Sign in to post a comment
Update
$Inhibikase Therapeutics(IKT.US$ Inhibikase Reports Preliminary Outcomes Of Pre-NDA Meeting With FDA On Pathway For Approval For IkT-001Pro In Blood And Gastrointestinal Cancers; Says Given Specific Guidance On Manufacturing Requirements Necessary To Complete NDA
1
1
Like!
$Inhibikase Therapeutics(IKT.US$ Inhibikase Therapeutics beat estimated earnings by 27.73%, reporting an EPS of $-0.86 versus an estimate of $-1.19.
Revenue was up $72 thousand from the same period last year.
Revenue was up $72 thousand from the same period last year.
1
$Inhibikase Therapeutics(IKT.US$ we've had our fast track and now waiting for updated news as to results. 10 steps ahead of $Genprex(GNPX.US$ who are having their FDA fast track pump now.
iKT pulled back and some after the FDA fast track news. Next step here might just be the BIG one as well as a ream of catalysts in toe.
Time for GNPX to bank and throw some into wealth creator IKT 😉
iKT pulled back and some after the FDA fast track news. Next step here might just be the BIG one as well as a ream of catalysts in toe.
Time for GNPX to bank and throw some into wealth creator IKT 😉
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
TrytosaveabitOP : We were pleased with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval," said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. "Our bioequivalence studies were presented to the FDA and we were given specific guidance on the manufacturing requirements necessary to complete the NDA. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and we plan to seek all 11 indications for which imatinib mesylate has been approved, including its use in children. There is significant work ahead of us as we discuss these details with potential commercialization partners and carry out the work needed for the NDA submission," noted Dr. Werner.